Assessing fatigue in myalgic encephalomyelitis/chronic fatigue syndrome patients before and after treatment with bright light therapy: A prospective randomized controlled crossover study. — CFSMEATLAS
Assessing fatigue in myalgic encephalomyelitis/chronic fatigue syndrome patients before and after treatment with bright light therapy: A prospective randomized controlled crossover study.
Ludwig, Birgit, Hauer, Lea, Böck, Marion et al. · Sleep medicine · 2025 · DOI
Quick Summary
Researchers tested whether bright light therapy—using special light boxes at home for two weeks—could help reduce fatigue in ME/CFS patients. While fatigue scores did improve immediately after the light therapy, these improvements did not remain significant when compared fairly to a waitlist control group. The study did find that bright light therapy may have helped patients concentrate better and react faster to tasks.
Why It Matters
ME/CFS patients urgently need effective treatments for disabling fatigue. This rigorous randomized controlled design with crossover methodology provides high-quality evidence about bright light therapy's actual efficacy, helping patients and clinicians make informed treatment decisions and highlighting the importance of placebo control in ME/CFS intervention trials.
Observed Findings
Fatigue scores improved immediately after 2 weeks of bright light therapy compared to baseline
In the controlled crossover analysis, fatigue improvement with BLT was not statistically significant versus waitlist
Patients showed decreased reaction time on TAP attention testing after BLT compared to waitlist control
Approximately 45% of study participants had concurrent postural tachycardia syndrome diagnosis
36 outpatients with IOM 2015-defined ME/CFS completed the crossover protocol
Inferred Conclusions
Two weeks of bright light therapy is not an effective treatment for primary fatigue symptom reduction in ME/CFS
Bright light therapy may provide secondary benefits for attention and reaction time in ME/CFS patients
Placebo effects are significant in ME/CFS fatigue assessment and require rigorous controlled designs
Postural tachycardia syndrome is a common comorbidity in ME/CFS requiring consideration in treatment protocols
Remaining Questions
Would longer durations of bright light therapy (beyond 2 weeks) produce sustained fatigue improvements?
What This Study Does Not Prove
This study does not prove that bright light therapy is ineffective for all ME/CFS patients or in longer treatment periods—only that 2 weeks of treatment did not produce sustained fatigue reduction in this specific sample. The improvement in attention does not necessarily translate to clinically meaningful functional benefits in daily life. The high rate of postural tachycardia comorbidity limits generalizability to all ME/CFS populations.